ATE358473T1 - Diamino-propanol-verbindungen zur behandlung von ischaemien - Google Patents
Diamino-propanol-verbindungen zur behandlung von ischaemienInfo
- Publication number
- ATE358473T1 ATE358473T1 AT99937409T AT99937409T ATE358473T1 AT E358473 T1 ATE358473 T1 AT E358473T1 AT 99937409 T AT99937409 T AT 99937409T AT 99937409 T AT99937409 T AT 99937409T AT E358473 T1 ATE358473 T1 AT E358473T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- diamino
- ischemia
- galt
- propanol compounds
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- LSRUBRSFDNKORM-UHFFFAOYSA-N 1,1-diaminopropan-1-ol Chemical class CCC(N)(N)O LSRUBRSFDNKORM-UHFFFAOYSA-N 0.000 title 1
- 208000028867 ischemia Diseases 0.000 title 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 abstract 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000000099 in vitro assay Methods 0.000 abstract 1
- 238000005462 in vivo assay Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9429898P | 1998-07-27 | 1998-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE358473T1 true ATE358473T1 (de) | 2007-04-15 |
Family
ID=22244359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99937409T ATE358473T1 (de) | 1998-07-27 | 1999-07-22 | Diamino-propanol-verbindungen zur behandlung von ischaemien |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6511979B1 (de) |
| EP (1) | EP1098642B1 (de) |
| JP (1) | JP2002521435A (de) |
| AT (1) | ATE358473T1 (de) |
| AU (1) | AU756008B2 (de) |
| CA (1) | CA2336549A1 (de) |
| DE (1) | DE69935720T2 (de) |
| ES (1) | ES2285852T3 (de) |
| WO (1) | WO2000006145A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303774B1 (en) * | 1999-08-20 | 2001-10-16 | Sri International | Nucleoside pyrophosphate and triphosphate analogs and related compounds |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| CA2434028C (en) | 2001-01-10 | 2010-11-09 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| DE60217835D1 (en) * | 2001-02-28 | 2007-03-15 | John H Griffin | Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c |
| JP4986335B2 (ja) * | 2001-05-15 | 2012-07-25 | 生化学工業株式会社 | Ｖｄａｃ機能阻害剤 |
| EP2266968B1 (de) | 2001-07-16 | 2013-01-09 | Genzyme Corporation | Synthese von UDP-Glukose: N-Acetylsphingosin Glikosyltransferase Inhibitoren |
| WO2003035102A1 (en) * | 2001-10-26 | 2003-05-01 | University Technologies International, Inc. | Use of egf to inhibit pathogenic infections of the urogenital tract |
| US6916802B2 (en) * | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| US20060217560A1 (en) * | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US8500751B2 (en) | 2004-03-31 | 2013-08-06 | Merlin Md Pte Ltd | Medical device |
| SG133420A1 (en) * | 2005-12-13 | 2007-07-30 | Merlin Md Pte Ltd | An endovascular device with membrane having permanently attached agents |
| WO2005094725A1 (en) | 2004-03-31 | 2005-10-13 | Merlin Md Pte Ltd | A method for treating aneurysms |
| US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| AU2005277186A1 (en) * | 2004-08-20 | 2006-03-02 | The Johns Hopkins University | Methods for treatment of angiogenesis |
| CA2586761A1 (en) * | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| JP2008521489A (ja) * | 2004-11-24 | 2008-06-26 | テラカイン コーポレイション | 眼球内薬物送達のための移植物 |
| CA2509083A1 (en) * | 2004-12-22 | 2006-06-22 | Merlin Md Pte Ltd | A medical device |
| EP2032134B1 (de) * | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese |
| US8304447B2 (en) | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| KR20160085917A (ko) | 2007-10-05 | 2016-07-18 | 젠자임 코포레이션 | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 |
| WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| PL3133070T3 (pl) | 2009-11-27 | 2020-01-31 | Genzyme Corporation | Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta |
| WO2011099980A1 (en) | 2010-02-12 | 2011-08-18 | The Johns Hopkins University | Use of the lactosylceramide synthase isoform b1, 4galt-v as a biomarker for cancer |
| US10987208B2 (en) | 2012-04-06 | 2021-04-27 | Merlin Md Pte Ltd. | Devices and methods for treating an aneurysm |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) * | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US5339567A (en) | 1993-06-22 | 1994-08-23 | Pierpont John M | Interior-mounted security bars |
| US5707649A (en) | 1993-08-13 | 1998-01-13 | Seikagaku Corporation | Agent for treating neuronal diseases |
| WO1995034530A1 (en) * | 1994-06-10 | 1995-12-21 | Seikagaku Corporation | 2-acylaminopropanol compound and medicinal composition |
| US5972928A (en) * | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
-
1999
- 1999-07-22 ES ES99937409T patent/ES2285852T3/es not_active Expired - Lifetime
- 1999-07-22 WO PCT/US1999/016667 patent/WO2000006145A1/en not_active Ceased
- 1999-07-22 AU AU52249/99A patent/AU756008B2/en not_active Ceased
- 1999-07-22 AT AT99937409T patent/ATE358473T1/de not_active IP Right Cessation
- 1999-07-22 EP EP99937409A patent/EP1098642B1/de not_active Expired - Lifetime
- 1999-07-22 CA CA002336549A patent/CA2336549A1/en not_active Abandoned
- 1999-07-22 US US09/359,023 patent/US6511979B1/en not_active Expired - Fee Related
- 1999-07-22 DE DE69935720T patent/DE69935720T2/de not_active Expired - Fee Related
- 1999-07-22 JP JP2000562000A patent/JP2002521435A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US6511979B1 (en) | 2003-01-28 |
| DE69935720T2 (de) | 2007-12-27 |
| EP1098642B1 (de) | 2007-04-04 |
| CA2336549A1 (en) | 2000-02-10 |
| AU756008B2 (en) | 2003-01-02 |
| EP1098642A4 (de) | 2004-08-18 |
| ES2285852T3 (es) | 2007-11-16 |
| DE69935720D1 (de) | 2007-05-16 |
| JP2002521435A (ja) | 2002-07-16 |
| AU5224999A (en) | 2000-02-21 |
| EP1098642A1 (de) | 2001-05-16 |
| WO2000006145A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE358473T1 (de) | Diamino-propanol-verbindungen zur behandlung von ischaemien | |
| SV1995000007A (es) | Derivados del acido micofenolico 5-substituidos. | |
| EA200101166A1 (ru) | Ингибиторы металлопротеаз | |
| TW200505901A (en) | Muscarinic agonists | |
| ES2194536T3 (es) | Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. | |
| AP2002002458A0 (en) | Compounds for the treatment of ischemia. | |
| NO20003600L (no) | Kalium kanal inhibitorer | |
| UA70958C2 (uk) | Спосіб лікування захворювання, пов'язаного з порушенням метаболізму естрогену (варіанти) | |
| TR199802136T2 (xx) | �MPDH enzimi inhibit�rleri olarak �re t�revleri. | |
| PE44895A1 (es) | Compuesto derivado de benzotiofeno que puede inhibir la perdida osea y disminuir el colesterol en suero | |
| BR0007527A (pt) | Fenilfenantridinas com atividade inibitória depde-iv | |
| ES2173858T3 (es) | Analogos de huperzina a. | |
| YU401A (sh) | Sredstva sa antidepresivnim dejstvom | |
| NO985232L (no) | Androstenderivater | |
| TR200002971T2 (tr) | İkameli pirolidin hidroksamat metaloproteaz inhibitörleri | |
| ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
| MY134888A (en) | Optically active isomers of ketotifen and therapeutically active metabolites thereof | |
| BR0012696A (pt) | Composição oftálmica | |
| DE69725882D1 (de) | Adenovirus e4 proteine für induktion von zelltod | |
| NO984950L (no) | Forbindelser med veksthormonfrigj°rende egenskaper | |
| ES2099747T3 (es) | Aplicacion topica terapeuticamente eficaz de la st1435. | |
| TR200101245T2 (tr) | N-arilsulfonil-aminoasit-omega-amidler | |
| DE69727583D1 (de) | Vermeidung von gastrointestinaler schädigung | |
| MXPA02004702A (es) | Analogos interrumpidos por heteroatomos de acido 15-hidroxieicosatetraenoico y metodos de uso. | |
| MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |